Agios Pharma (GB:0HB0)
UK Market

Agios Pharma Stock Analysis & Ratings

GB:0HB0 Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$22.71
Average Volume (3M)59.00
Market Cap$1.24B
P/E RatioN/A
Next EarningsAug 04, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)0.00



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Agios Pharma’s market cap?
    Agios Pharma’s market cap is $1.24B.
      What is Agios Pharma’s price target?
      The average price target for Agios Pharma is $48.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $96.00 ,the lowest forecast is $23.00. The average price target represents 114.88% Increase from the current price of $22.71.
        What do analysts say about Agios Pharma?
        Agios Pharma’s analyst rating consensus is a ‘Hold. This is based on the ratings of 6 Wall Streets Analysts.
          When is Agios Pharma’s upcoming earnings report date?
          Agios Pharma’s upcoming earnings report date is Aug 04, 2022 which is in 80 days.
            How were Agios Pharma’s earnings last quarter?
            Agios Pharma released its earnings results on May 05, 2022. The company reported -$1.74 earnings per share for the quarter, the consensus estimate of -$1.74 by $0.
              Is Agios Pharma overvalued?
              According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
                Does Agios Pharma pay dividends?
                Agios Pharma does not currently pay dividends.
                What is Agios Pharma’s EPS estimate?
                Agios Pharma’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Agios Pharma have?
                Agios Pharma has 54,790,000 shares outstanding.
                  What happened to Agios Pharma’s price movement after its last earnings report?
                  Agios Pharma reported an EPS of -$1.74 in its last earnings report, expectations of -$1.74. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Agios Pharma?
                    Among the largest hedge funds holding Agios Pharma’s share is Farallon Capital Management, L.L.C.. It holds Agios Pharma’s shares valued at 41M.


                      Agios Pharma Stock Analysis

                      Smart Score
                      Price Target
                      ▲(114.88% Upside)
                      The Agios Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Agios Pharma

                      Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

                      Similar Stocks
                      Price & Change
                      Calithera Bio

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis